ABALLI JOHN
Known title: President and CEOCIK: 0001843113
ABALLI JOHN's purchase track record
How the stock did after each of ABALLI JOHN's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
Purchases measured
3
of 3 since December 8, 2022
Stock higher 6 months later
100%
3 months: 67%
Median 6-month return
+53.4%
3 months: +47.2%
Beat the S&P 500
100%
median +41.1% vs. index
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 11/14/2024 | XGN | $68K | +47.2% | +97.9% | -0.5% |
| 5/16/2024 | XGN | $78K | +49.7% | +53.4% | +12.3% |
| 12/8/2022 | XGN | $241K | -5.8% | +24.1% | +8.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| XGN | ▲ Buy | Grant | 150,000 | $0 | 3/12/2026 | View on chart |
| XGN | ▼ Sell | Open Market | 15,698 | $57K | 3/3/2026 | View on chart |
| XGN | ▲ Buy | Grant | 2,535 | $8K | 3/3/2026 | View on chart |
| XGN | ▼ Sell | Open Market | 11,430 | $41K | 2/24/2026 | View on chart |
| XGN | ▼ Sell | Open Market | 31,787 | $376K | 10/16/2025 | View on chart |
| XGN | ▲ Buy | Grant | 8,621 | $21K | 2/28/2025 | View on chart |
| XGN | ▲ Buy | Grant | 112,500 | $0 | 2/21/2025 | View on chart |
| XGN | ▲ Buy | Open Market | 24,305 | $68K | 11/14/2024 | View on chart |
| XGN | ▲ Buy | Open Market | 40,401 | $78K | 5/16/2024 | View on chart |
| XGN | ▲ Buy | Grant | 9,804 | $19K | 2/29/2024 | View on chart |
| XGN | ▲ Buy | Grant | 175,000 | $0 | 2/20/2024 | View on chart |
| XGN | ▼ Sell | Open Market | 33,819 | $59K | 10/17/2023 | View on chart |
| XGN | ▲ Buy | Grant | 9,803 | $21K | 8/31/2023 | View on chart |
| XGN | ▲ Buy | Open Market | 90,000 | $241K | 12/8/2022 | View on chart |
| XGN | ▲ Buy | Grant | 350,000 | $0 | 10/16/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
TD Cowen Raises Exagen Price Target to $11
TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.
TD Cowen Raises Exagen Price Target to $11. TD Cowen has maintained its positive stance on Exagen, raising its price target to $11. This update aligns with the broader analyst consensus, where the average target sits at $10.14. The move provides context for the stock's current position within its 52-week range of $2.59 to $12.23.